CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- S-3ASR Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $18.24 ($121,616)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at an average $20.46 ($66,504)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.29 ($278,646)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at an average $22.52 ($281,518)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.66 ($22,655)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $19.79 ($131,951)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at an average $20.91 ($67,956)
- 144 Insider Sale of Securities
- 8-K Event Shareholder vote results
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $21.40 ($267,458)
Page 9 of 40 · 798 filings